The Food and Drug Administration today withdrew approval for Makena and its generics, citing a confirmatory study that did not verify clinical benefit. Makena had been approved under the FDA’s accelerated approval pathway to reduce the risk of preterm birth in women pregnant with one baby who have a history of spontaneous preterm birth. Makena and its generics cannot lawfully be distributed in interstate commerce, effective immediately. FDA is aware that some products have already been distributed, so health care providers should talk to their patients, if applicable.

Headline
A new AHA toolkit offers practical strategies to strengthen rural maternal care, drawing on insights from 160 leaders representing 92 hospitals and health…
Headline
The Food and Drug Administration Oct. 29 issued a proposed rule to update infant formula nutrient requirements, the first such update since 1998. The proposal…
Headline
Extending Medicaid coverage by 12 months following childbirth increased use of postpartum care among mothers with pregnancy complications such as diabetes and…
Headline
A new blog, part of the Keeping Care Close to Home initiative, discusses how connected care networks are essential to sustaining rural maternal care. The blog…
Blog
When the American Hospital Association launched the Keeping Care Close to Home: Innovations in Rural Maternal Health project in 2025, we set out to understand…
Headline
The Department of Health and Human Services Oct. 9 announced the launch of its Newborn Essentials Support Toolkit Program, which, through partnership with the…